- Home
- PBPB vs ADCT Comparison
PBPB vs ADCT Comparison
Compare PBPB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- ADCT
- Stock Information
- Founded
- PBPB 1977
- ADCT 2011
- Country
- PBPB United States
- ADCT Switzerland
- Employees
- PBPB N/A
- ADCT N/A
- Industry
- PBPB Restaurants
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- ADCT Health Care
- Exchange
- PBPB Nasdaq
- ADCT Nasdaq
- Market Cap
- PBPB 305.0M
- ADCT 241.0M
- IPO Year
- PBPB 2013
- ADCT 2020
- Fundamental
- Price
- PBPB $12.25
- ADCT $2.71
- Analyst Decision
- PBPB Strong Buy
- ADCT Strong Buy
- Analyst Count
- PBPB 3
- ADCT 6
- Target Price
- PBPB $15.67
- ADCT $7.80
- AVG Volume (30 Days)
- PBPB 233.9K
- ADCT 1.0M
- Earning Date
- PBPB 08-07-2025
- ADCT 08-05-2025
- Dividend Yield
- PBPB N/A
- ADCT N/A
- EPS Growth
- PBPB 1009.90
- ADCT N/A
- EPS
- PBPB 1.39
- ADCT N/A
- Revenue
- PBPB $465,126,000.00
- ADCT $75,817,000.00
- Revenue This Year
- PBPB $4.74
- ADCT $10.65
- Revenue Next Year
- PBPB $4.48
- ADCT $15.05
- P/E Ratio
- PBPB $8.82
- ADCT N/A
- Revenue Growth
- PBPB N/A
- ADCT 10.49
- 52 Week Low
- PBPB $6.28
- ADCT $1.05
- 52 Week High
- PBPB $13.48
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- PBPB 65.44
- ADCT 46.56
- Support Level
- PBPB $10.51
- ADCT $2.59
- Resistance Level
- PBPB $12.18
- ADCT $2.98
- Average True Range (ATR)
- PBPB 0.43
- ADCT 0.31
- MACD
- PBPB 0.04
- ADCT -0.15
- Stochastic Oscillator
- PBPB 80.84
- ADCT 8.70
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).